Trial Profile

A phase 2 study of Azercabtagene zapreleucel in CAR T Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Aug 2023 According to a Precision BioSciences media release, the company announced completion of a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel). Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.
27 Jul 2023 According to a Precision BioSciences media release, the company has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) to gain further clarity on the potential registration path for azer-cel including study design, endpoints and the recommended phase 2 dose for the CAR T relapsed patient setting.
06 Jun 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com